Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
15073 | 664 | 46.7 | 91% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
880 | 10788 | HEREDITARY HEMORRHAGIC TELANGIECTASIA//ENDOGLIN//TGF BETA |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ENDOGLIN | Author keyword | 139 | 51% | 30% | 197 |
2 | CD105 | Author keyword | 43 | 42% | 12% | 79 |
3 | TRC105 | Author keyword | 30 | 100% | 2% | 12 |
4 | CD105 ENDOGLIN | Author keyword | 10 | 52% | 2% | 13 |
5 | ALK1 | Author keyword | 9 | 36% | 3% | 21 |
6 | SOLUBLE CD105 | Author keyword | 8 | 100% | 1% | 5 |
7 | RENAL CARDIOVASC UNIT | Address | 6 | 80% | 1% | 4 |
8 | ANTI ENDOGLIN ANTIBODY | Author keyword | 4 | 75% | 0% | 3 |
9 | ACTIVIN RECEPTOR LIKE KINASE 1 | Author keyword | 4 | 36% | 1% | 9 |
10 | ENDOGLIN CD105 | Author keyword | 4 | 41% | 1% | 7 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ENDOGLIN | 139 | 51% | 30% | 197 | Search ENDOGLIN | Search ENDOGLIN |
2 | CD105 | 43 | 42% | 12% | 79 | Search CD105 | Search CD105 |
3 | TRC105 | 30 | 100% | 2% | 12 | Search TRC105 | Search TRC105 |
4 | CD105 ENDOGLIN | 10 | 52% | 2% | 13 | Search CD105+ENDOGLIN | Search CD105+ENDOGLIN |
5 | ALK1 | 9 | 36% | 3% | 21 | Search ALK1 | Search ALK1 |
6 | SOLUBLE CD105 | 8 | 100% | 1% | 5 | Search SOLUBLE+CD105 | Search SOLUBLE+CD105 |
7 | ANTI ENDOGLIN ANTIBODY | 4 | 75% | 0% | 3 | Search ANTI+ENDOGLIN+ANTIBODY | Search ANTI+ENDOGLIN+ANTIBODY |
8 | ACTIVIN RECEPTOR LIKE KINASE 1 | 4 | 36% | 1% | 9 | Search ACTIVIN+RECEPTOR+LIKE+KINASE+1 | Search ACTIVIN+RECEPTOR+LIKE+KINASE+1 |
9 | ENDOGLIN CD105 | 4 | 41% | 1% | 7 | Search ENDOGLIN+CD105 | Search ENDOGLIN+CD105 |
10 | ALK1 ACVRL1 | 3 | 100% | 0% | 3 | Search ALK1+ACVRL1 | Search ALK1+ACVRL1 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BINDING PROTEIN ENDOGLIN | 87 | 94% | 5% | 31 |
2 | HEREDITARY HEMORRHAGIC TELANGIECTASIA | 39 | 18% | 30% | 197 |
3 | RGD CONTAINING GLYCOPROTEIN | 30 | 62% | 5% | 31 |
4 | ENDOGLIN CD105 | 23 | 38% | 7% | 47 |
5 | RECEPTOR LIKE KINASE 1 | 22 | 41% | 6% | 43 |
6 | CD105 | 21 | 44% | 6% | 37 |
7 | ENDOGLIN | 14 | 18% | 10% | 67 |
8 | CD105 EXPRESSION | 12 | 45% | 3% | 21 |
9 | PHOSPHORYLATED SMAD2 3 | 11 | 100% | 1% | 6 |
10 | CD105 MONOCLONAL ANTIBODIES | 11 | 78% | 1% | 7 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Endoglin (CD105): A marker of tumor vasculature and potential target for therapy | 2008 | 142 | 62 | 89% |
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours | 2010 | 78 | 96 | 84% |
Endoglin-Targeted Cancer Therapy | 2011 | 51 | 66 | 82% |
Endoglin in angiogenesis and vascular diseases | 2008 | 119 | 118 | 61% |
Endoglin (CD105): A Review of its Role in Angiogenesis and Tumor Diagnosis, Progression and Therapy | 2011 | 52 | 98 | 73% |
Review: The enigmatic role of endoglin in the placenta | 2014 | 6 | 44 | 66% |
CD105 is important for angiogenesis: evidence and potential applications | 2003 | 287 | 74 | 64% |
Signaling by members of the TGF-beta family in vascular morphogenesis and disease | 2010 | 107 | 88 | 34% |
The emerging role of TGF-beta superfamily coreceptors in cancer | 2009 | 91 | 269 | 46% |
The physiological role of endoglin in the cardiovascular system | 2010 | 39 | 169 | 60% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RENAL CARDIOVASC UNIT | 6 | 80% | 0.6% | 4 |
2 | REINA SOFIA INVEST NEFROL | 4 | 13% | 3.9% | 26 |
3 | RENAL CARDIOVASC PHYSIOPATHOL UNIT | 3 | 57% | 0.6% | 4 |
4 | HEART STROKE LEWAR EXCELLENCE | 3 | 60% | 0.5% | 3 |
5 | CANC BIOL SURG | 2 | 67% | 0.3% | 2 |
6 | HAINAN PROVINCIAL TROP MED | 2 | 67% | 0.3% | 2 |
7 | HEART STROKE FDN RICHARD LEWAR EXCELLENCE | 2 | 67% | 0.3% | 2 |
8 | MOL STRUCT FUNCT PROGRAM | 2 | 11% | 2.1% | 14 |
9 | UNIDAD FISIOPATOL RENAL CARDIOVASC | 1 | 18% | 0.8% | 5 |
10 | ANAT HISTOL HUMANAS | 1 | 13% | 1.1% | 7 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000233699 | HEREDITARY HEMORRHAGIC TELANGIECTASIA//PULMONARY ARTERIOVENOUS MALFORMATION//HEREDITARY HAEMORRHAGIC TELANGIECTASIA |
2 | 0.0000182841 | MICROVESSEL DENSITY//MICROVESSEL COUNT//CHALKLEY |
3 | 0.0000177068 | CTHRC1//COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1//CAROTID ARTERY RESTENOSIS |
4 | 0.0000121389 | ANTIANGIOGENIC CANCER VACCINE//CELL PROTEOMIC FOOTPRINTING//HER1 VACCINE |
5 | 0.0000084691 | DELTA LIKE LIGAND 4//DLL4//ARTERIAL VENOUS DIFFERENTIATION |
6 | 0.0000082492 | GREMLIN//AFFILIATED XIANG YA HOSP//BMP9 |
7 | 0.0000081361 | SMAD//SMAD4//SNON |
8 | 0.0000076823 | VASCULOGENIC MIMICRY//TIANJIN CANC HOSP//TEM7 |
9 | 0.0000069381 | TGF BETA RECEPTORS//TGF BETA RECEPTOR//MED MED CELL BIOL |
10 | 0.0000068809 | ALK5 INHIBITOR//CELL BASED LUCIFERASE REPORTER ASSAY//TGFB1 |